Below is a snipit from a large document on Symmetrical Immune Network Theory, and as I mentioned earlier, I-J Paradox.
Please read this, as it may be a quantum step towards understanding bavituximab and systemic immune responses, or lack there of, IMO.
More to come regarding my take on Bavituximab, tumor vasc, and the tumor microenvironment. The truth..
"The phenomena of how the system can respond to increasing doses of antigen has been a challenge for theorists since Mitchison showed that small or large doses of an antigen can cause smaller immune responses than intermediate doses of antigen (14). Low dose tolerance also refers to the phenomenon that low priming doses of an antigen can result in a weak response to a subsequent otherwise immunogenic dose of antigen (15). This low dose tolerance phenomenon is a paradox in the context of clonal selection, without taking account of network interactions. In the context of the symmetrical network theory we can explain low and high dose tolerance as follows".
"Clonal Selection", a phenomenon also explained by clonal selection. This is the organism’s ability to tolerate the introduction of cells without an immune response as long as this occurs early in the organism’s development. There are a vast number of lymphocytes occurring in the immune system ranging from cells which are tolerant of self tissue to cells which are not tolerant of self tissue. However, only cells that are tolerant to self tissue will survive the embryonic stage. If non-self tissue is introduced, the lymphocytes which develop will be the ones which included the non-self tissues as self tissue
News 
Market Data 
Discover 
AI
